Integra LifeSciences (IART)
(Delayed Data from NSDQ)
$27.54 USD
+0.05 (0.18%)
Updated May 17, 2024 04:00 PM ET
After-Market: $27.53 -0.01 (-0.04%) 7:58 PM ET
4-Sell of 5 4
A Value F Growth F Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
IART 27.54 +0.05(0.18%)
Will IART be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for IART based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IART
Deciphering Integra (IART) International Revenue Trends
Integra's (IART) Q1 Earnings Match Estimates, Margins Down
IART: What are Zacks experts saying now?
Zacks Private Portfolio Services
Integra (IART) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
Edwards Lifesciences (EW) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Earnings Preview: Integra LifeSciences (IART) Q1 Earnings Expected to Decline
Other News for IART
IART July 19th Options Begin Trading
Integra LifeSciences to Present at the 2024 Bank of America Healthcare Conference
Integra LifeSciences: Expansion, Audits, and Share Repurchase Plan
Integra Lifesciences (IART) Receives a Sell from J.P. Morgan
Target upgraded, CVS downgraded: Wall Street's top analyst calls